Nationwide SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era, 2021-2022: an Ongoing Prospective Cohort Study

Eric R.A. Vos; Cheyenne C.E. van Hagen; Denise Wong; Gaby Smits; Marjan Kuijer; Alienke J. Wijmenga-Monsuur; Joanna Kaczorowska; Robert S. van Binnendijk; Fiona R.M. van der Klis; Gerco den Hartog; Hester E. de Melker

doi:10.1101/2023.11.22.23298889

Article Information

doi

https://doi.org/10.1101/2023.11.22.23298889

History

November 22, 2023.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Eric R.A. Vos1,*,
Cheyenne C.E. van Hagen1,
Denise Wong1,
Gaby Smits2,
Marjan Kuijer2,
Alienke J. Wijmenga-Monsuur2,
Joanna Kaczorowska2,
Robert S. van Binnendijk2,
Fiona R.M. van der Klis2,
Gerco den Hartog2,3 and
Hester E. de Melker1

¹Centre for Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
²Centre for Immunology of Infectious Diseases and Vaccines, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
³Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, the Netherlands